Title(s):
Associate Professor of Oncology
Associate Professor of Pediatrics
Associate Professor of Pediatrics
Director of the Musculoskeletal Tumor Program
Appointment Phone:
410-955-8751
Primary Location:
The Johns Hopkins Hospital
Expertise:
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Transplant, Bone Tumors, Cancer, Chronic Myeloid Leukemia, Clinical Trials, Ewing's Sarcoma, Graft-versus-Host Disease, Hematologic Malignancies, Hodgkin's Disease, Leukemia, Leukemia/Lymphoma, Medical Oncology, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Osteosarcoma, Pediatric Oncology, Rhabdomyosarcoma, Sarcoma, Soft Tissue Sarcoma, Soft Tissue Tumors
Education and Experience
Training
- Columbia University College of Physicians and Surgeons (New York NY)/ (1994)
Residencies
- The Johns Hopkins Hospital (Baltimore MD)/ Pediatrics (1997)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Clinical Fellow / Pediatic Oncology (2000)
Certifications
- Pediatric Hematology/Oncology, American Board of Pediatrics (2008)
Locations
The Johns Hopkins Hospital
600 N. Wolfe Street
Hospital Main Entrance - Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-502-7247
Appointment Phone: 410-955-8751
Location Map
Johns Hopkins Outpatient Center
601 N. Caroline Street
Baltimore, MD 21287
Appointment Phone: 410-955-8751
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Pediatric Oncology
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
Undergraduate degree, BA in Biology from Johns Hopkins University in 1987. PhD from Columbia University, 1993. MD from Columbia University, 1994. Internship and Residency in Pediatrics, Johns Hopkins University 1994-1997. Fellowship in Pediatric Hematology/Oncology, Johns Hopkins University, 1997-2000. Faculty, Johns Hopkins University, 2000-present.
Physician Title
Director of the Musculoskeletal Tumor Program
Awards and Honors
The Justin Strauss Chordoma Research Award, 2009
Expertise
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Aplastic Anemia
- Bone Marrow Transplant
- Bone Tumors
- Cancer
- Chronic Myeloid Leukemia
- Clinical Trials
- Ewing's Sarcoma
- Graft-versus-Host Disease
- Hematologic Malignancies
- Hodgkin's Disease
- Leukemia
- Leukemia/Lymphoma
- Medical Oncology
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma
- Osteosarcoma
- Pediatric Oncology
- Rhabdomyosarcoma
- Sarcoma
- Soft Tissue Sarcoma
- Soft Tissue Tumors
Research
Research and Publications
Research Summary
Dr. Loeb has active laboratory and clinical research efforts. In the laboratory, Dr. Loeb studies a gene called WT1. High levels of WT1 convey a poor prognosis for patients with osteosarcoma and soft tissue sarcomas. Dr. Loebs laboratory has shown that WT1 expression is regulated, in part, by the amount of oxygen in a tumor, and that low oxygen levels lead to higher WT1 expression, which in turn leads to an increase in the ability of tumor cells to cause new blood vessels to form. The laboratory is studying both the mechanism by which oxygen levels control WT1 expression and the way WT1 regulates blood vessel growth. In a related project, Dr. Loebs laboratory is working to identify, characterize, and therapeutically target Ewing sarcoma stem cells. Cancer stem cells are thought to be inherently resistant to chemotherapy and are thought to cause most cases of refractory or relapsed disease. In collaboration with the laboratory of Dr. Jonathan Powell, Dr. Loeb has identified one pathway, called the mTOR signaling pathway, that may be important for sarcoma stem cells to resist chemotherapy. This finding prompted the initiation of a clinical trial, led by Dr. Loeb, to test the combination of Doxil, a standard chemotherapy drug, and Temsirolimus, an inhibitor of the mTOR signaling pathway, in patients with high risk sarcomas. Future clinical trials, already being planned, will test additional means by which the inherent chemoresistance of these key cells can be overcome, hopefully leading to significant improvements in the survival of patients with recurrent or refractory sarcomas.
Journal Citations
Savage, W.J.; DeRusso, P.A.; Resar, L.M.; Chen, A.R.; Higman, M.A.; Loeb, D.M.; Jones, R.J.; Brodsky, R.A. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer. 2007 Dec;49(7):947-951.
Loeb, S.; Chan, D.W.; Sokoll, L.; Kan, D.; Maggiore, J.; Mikolajczyk, S.D.; Mondo, D.M.; Griffin, C.R.; Catalona, W.J. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol. 2008 Nov;180(5):1959-1962; discussion 1962-1953.
Loeb, S.; Hernandez, D.J.; Mangold, L.A.; Humphreys, E.B.; Agro, M.; Walsh, P.C.; Partin, A.W.; Han, M. Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int. 2008 Jun;101(12):1503-1506.
Loeb, S.; Kettermann, A.; Carter, H.B.; Ferrucci, L.; Metter, E.J.; Walsh, P.C. Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol. 2008 Oct;180(4):1314-1317; discussion 1317.
Loeb, S.; Kettermann, A.; Ferrucci, L.; Landis, P.; Metter, E.J.; Carter, H.B. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol. 2008 Nov;54(5):1073-1080.
Loeb, S.; Partin, A.W. Single nucleotide polymorphisms and prostate cancer susceptibility. Rev Urol. 2008 Fall;10(4):304-305.
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for Prostate Cancer. Annual review of medicine. 2008 Oct 23.
Brawer, M.K.; Loeb, S.; Partin, A.W.; Yoshimura, N.; Chancellor, M.B.; Roehrborn, C.G.; Assimos, D.G.; Nickel, J.C.; Shuch, B.; Pouliot, F.; Belldegrun, A.S.; Shapiro, E. Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring;11(2):82-107.
Loeb, D.M.; Garrett-Mayer, E.; Hobbs, R.F.; Prideaux, A.R.; Sgouros, G.; Shokek, O.; Wharam, M.D., Jr.; Scott, T.; Schwartz, C.L. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009 Jun 1;115(11):2514-2522.
Loeb, S.; Carter, H.B. Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. Eur Urol. 2009 Feb;55(2):523-524.
Loeb, S.; Carter, H.B. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Urol Oncol. 2009 Nov-Dec;27(6):583-584.
Loeb, S.; Carter, H.B.; Schaeffer, E.M.; Ferrucci, L.; Kettermann, A.; Metter, E.J. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Dec;182(6):2646-2651.
Loeb, S.; Carter, H.B.; Walsh, P.C.; Isaacs, W.B.; Kettermann, A.; Tanaka, T.; Ferrucci, L.; Metter, E.J. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol. 2009 Jul;182(1):101-104; discussion 105.
Loeb, S.; Epstein, J.I.; Humphreys, E.B.; Walsh, P.C. Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes? BJU Int. 2009 Aug 19.
Loeb, S.; Helfand, B.T.; Kan, D.; Isaacs, W.B.; Catalona, W.J. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? BJU Int. 2009 Nov;104(9):1200-1203.
Loeb, S.; Kettermann, A.; Carter, H.B.; Ferrucci, L.; Metter, E.J.; Walsh, P.C. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Oct;182(4):1458-1462.
Loeb, S.; Partin, A.W. Randomized trials of selenium, vitamin e, or vitamin C for prostate cancer prevention. Rev Urol. 2009 Spring;11(2):114-115.
Loeb, S.; Partin, A.W. Randomized trials of prostate cancer screening. Rev Urol. 2009 Summer;11(3):179-180.
Loeb, S.; Schaeffer, E.M. Risk factors, prevention and early detection of prostate cancer. Primary care. 2009 Sep;36(3):603-621.
Loeb, S.; Schaeffer, E.M. Optimal therapy in localized prostate cancer: an unfolding story. Oncology (Williston Park). 2009 Sep;23(10):843, 846.
Loeb, S.; Schaeffer, E.M.; Chan, D.W.; Carter, H.B.; Walsh, P.C.; Sokoll, L.J. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology. 2009 May;73(5):947-949.
Loeb, S.; Schaeffer, E.M.; Trock, B.J.; Epstein, J.I.; Humphreys, E.B.; Walsh, P.C. What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? Urology. 2009 Nov 19.
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for prostate cancer. Annual review of medicine. 2009;60:139-151.
Noronha, S.A.; Farrar, J.E.; Alonzo, T.A.; Gerbing, R.B.; Lacayo, N.J.; Dahl, G.V.; Ravindranath, Y.; Arceci, R.J.; Loeb, D.M. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Dec;53(6):1136-1139.
Schaeffer, E.M.; Carter, H.B.; Kettermann, A.; Loeb, S.; Ferrucci, L.; Landis, P.; Trock, B.J.; Metter, E.J. Prostate specific antigen testing among the elderly-when to stop? J Urol. 2009 Apr;181(4):1606-1614; discussion 1613-1604.
Tosoian, J.J.; Loeb, S.; Kettermann, A.; Landis, P.; Elliot, D.J.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Sokoll, L.J. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. J Urol. 2009 Dec 12.
Trock, B.J.; Guo, C.C.; Gonzalgo, M.L.; Magheli, A.; Loeb, S.; Epstein, J.I. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol. 2009 Oct;182(4):1364-1370.
Hobbs, R.F.; Baechler, S.; Senthamizhchelvan, S.; Prideaux, A.R.; Esaias, C.E.; Reinhardt, M.; Frey, E.C.; Loeb, D.M.; Sgouros, G. A gamma camera count rate saturation correction method for whole-body planar imaging. Phys Med Biol. 2010 Feb 7;55(3):817-831.
Hobbs, R.F.; McNutt, T.; Baechler, S.; He, B.; Esaias, C.E.; Frey, E.C.; Loeb, D.M.; Wahl, R.L.; Shokek, O.; Sgouros, G. A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. Int J Radiat Oncol Biol Phys. 2010 Oct 13.
Loeb, D.M.; Hobbs, R.F.; Okoli, A.; Chen, A.R.; Cho, S.; Srinivasan, S.; Sgouros, G.; Shokek, O.; Wharam, M.D., Jr.; Scott, T.; Schwartz, C.L. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer. 2010 Dec 1;116(23):5470-5478.
Loeb, S.; Makarov, D.V.; Schaeffer, E.M.; Humphreys, E.B.; Walsh, P.C. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. J Urol. 2010 Jul;184(1):157-161.
Loeb, S.; Partin, A.W. Open versus minimally invasive radical prostatectomy. Rev Urol. 2010 Winter;12(1):64-65.
Loeb, S.; Partin, A.W. What is the true mortality benefit of prostate-specific antigen screening? Rev Urol. 2010 Winter;12(1):66-67.
Loeb, S.; Partin, A.W. PCA3 Urinary Biomarker for Prostate Cancer. Rev Urol. 2010 Fall;12(4):e205-206.
Loeb, S.; Partin, A.W.; Schaeffer, E.M. Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? Rev Urol. 2010 Winter;12(1):20-24.
Loeb, S.; Schaeffer, E.M.; Epstein, J.I. The vanishing prostate cancer phenomenon. Urology. 2010 Sep;76(3):605-607.
Schaeffer, E.M.; Loeb, S.; Walsh, P.C. The case for open radical prostatectomy. Urol Clin North Am. 2010 Feb;37(1):49-55, Table of Contents.
Dr. Loeb has active laboratory and clinical research efforts. In the laboratory, Dr. Loeb studies a gene called WT1. High levels of WT1 convey a poor prognosis for patients with osteosarcoma and soft tissue sarcomas. Dr. Loebs laboratory has shown that WT1 expression is regulated, in part, by the amount of oxygen in a tumor, and that low oxygen levels lead to higher WT1 expression, which in turn leads to an increase in the ability of tumor cells to cause new blood vessels to form. The laboratory is studying both the mechanism by which oxygen levels control WT1 expression and the way WT1 regulates blood vessel growth. In a related project, Dr. Loebs laboratory is working to identify, characterize, and therapeutically target Ewing sarcoma stem cells. Cancer stem cells are thought to be inherently resistant to chemotherapy and are thought to cause most cases of refractory or relapsed disease. In collaboration with the laboratory of Dr. Jonathan Powell, Dr. Loeb has identified one pathway, called the mTOR signaling pathway, that may be important for sarcoma stem cells to resist chemotherapy. This finding prompted the initiation of a clinical trial, led by Dr. Loeb, to test the combination of Doxil, a standard chemotherapy drug, and Temsirolimus, an inhibitor of the mTOR signaling pathway, in patients with high risk sarcomas. Future clinical trials, already being planned, will test additional means by which the inherent chemoresistance of these key cells can be overcome, hopefully leading to significant improvements in the survival of patients with recurrent or refractory sarcomas.
Journal Citations
Savage, W.J.; DeRusso, P.A.; Resar, L.M.; Chen, A.R.; Higman, M.A.; Loeb, D.M.; Jones, R.J.; Brodsky, R.A. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer. 2007 Dec;49(7):947-951.
Loeb, S.; Chan, D.W.; Sokoll, L.; Kan, D.; Maggiore, J.; Mikolajczyk, S.D.; Mondo, D.M.; Griffin, C.R.; Catalona, W.J. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol. 2008 Nov;180(5):1959-1962; discussion 1962-1953.
Loeb, S.; Hernandez, D.J.; Mangold, L.A.; Humphreys, E.B.; Agro, M.; Walsh, P.C.; Partin, A.W.; Han, M. Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int. 2008 Jun;101(12):1503-1506.
Loeb, S.; Kettermann, A.; Carter, H.B.; Ferrucci, L.; Metter, E.J.; Walsh, P.C. Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol. 2008 Oct;180(4):1314-1317; discussion 1317.
Loeb, S.; Kettermann, A.; Ferrucci, L.; Landis, P.; Metter, E.J.; Carter, H.B. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol. 2008 Nov;54(5):1073-1080.
Loeb, S.; Partin, A.W. Single nucleotide polymorphisms and prostate cancer susceptibility. Rev Urol. 2008 Fall;10(4):304-305.
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for Prostate Cancer. Annual review of medicine. 2008 Oct 23.
Brawer, M.K.; Loeb, S.; Partin, A.W.; Yoshimura, N.; Chancellor, M.B.; Roehrborn, C.G.; Assimos, D.G.; Nickel, J.C.; Shuch, B.; Pouliot, F.; Belldegrun, A.S.; Shapiro, E. Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring;11(2):82-107.
Loeb, D.M.; Garrett-Mayer, E.; Hobbs, R.F.; Prideaux, A.R.; Sgouros, G.; Shokek, O.; Wharam, M.D., Jr.; Scott, T.; Schwartz, C.L. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009 Jun 1;115(11):2514-2522.
Loeb, S.; Carter, H.B. Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. Eur Urol. 2009 Feb;55(2):523-524.
Loeb, S.; Carter, H.B. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. Urol Oncol. 2009 Nov-Dec;27(6):583-584.
Loeb, S.; Carter, H.B.; Schaeffer, E.M.; Ferrucci, L.; Kettermann, A.; Metter, E.J. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Dec;182(6):2646-2651.
Loeb, S.; Carter, H.B.; Walsh, P.C.; Isaacs, W.B.; Kettermann, A.; Tanaka, T.; Ferrucci, L.; Metter, E.J. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol. 2009 Jul;182(1):101-104; discussion 105.
Loeb, S.; Epstein, J.I.; Humphreys, E.B.; Walsh, P.C. Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes? BJU Int. 2009 Aug 19.
Loeb, S.; Helfand, B.T.; Kan, D.; Isaacs, W.B.; Catalona, W.J. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? BJU Int. 2009 Nov;104(9):1200-1203.
Loeb, S.; Kettermann, A.; Carter, H.B.; Ferrucci, L.; Metter, E.J.; Walsh, P.C. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009 Oct;182(4):1458-1462.
Loeb, S.; Partin, A.W. Randomized trials of selenium, vitamin e, or vitamin C for prostate cancer prevention. Rev Urol. 2009 Spring;11(2):114-115.
Loeb, S.; Partin, A.W. Randomized trials of prostate cancer screening. Rev Urol. 2009 Summer;11(3):179-180.
Loeb, S.; Schaeffer, E.M. Risk factors, prevention and early detection of prostate cancer. Primary care. 2009 Sep;36(3):603-621.
Loeb, S.; Schaeffer, E.M. Optimal therapy in localized prostate cancer: an unfolding story. Oncology (Williston Park). 2009 Sep;23(10):843, 846.
Loeb, S.; Schaeffer, E.M.; Chan, D.W.; Carter, H.B.; Walsh, P.C.; Sokoll, L.J. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology. 2009 May;73(5):947-949.
Loeb, S.; Schaeffer, E.M.; Trock, B.J.; Epstein, J.I.; Humphreys, E.B.; Walsh, P.C. What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? Urology. 2009 Nov 19.
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for prostate cancer. Annual review of medicine. 2009;60:139-151.
Noronha, S.A.; Farrar, J.E.; Alonzo, T.A.; Gerbing, R.B.; Lacayo, N.J.; Dahl, G.V.; Ravindranath, Y.; Arceci, R.J.; Loeb, D.M. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Dec;53(6):1136-1139.
Schaeffer, E.M.; Carter, H.B.; Kettermann, A.; Loeb, S.; Ferrucci, L.; Landis, P.; Trock, B.J.; Metter, E.J. Prostate specific antigen testing among the elderly-when to stop? J Urol. 2009 Apr;181(4):1606-1614; discussion 1613-1604.
Tosoian, J.J.; Loeb, S.; Kettermann, A.; Landis, P.; Elliot, D.J.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Sokoll, L.J. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. J Urol. 2009 Dec 12.
Trock, B.J.; Guo, C.C.; Gonzalgo, M.L.; Magheli, A.; Loeb, S.; Epstein, J.I. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol. 2009 Oct;182(4):1364-1370.
Hobbs, R.F.; Baechler, S.; Senthamizhchelvan, S.; Prideaux, A.R.; Esaias, C.E.; Reinhardt, M.; Frey, E.C.; Loeb, D.M.; Sgouros, G. A gamma camera count rate saturation correction method for whole-body planar imaging. Phys Med Biol. 2010 Feb 7;55(3):817-831.
Hobbs, R.F.; McNutt, T.; Baechler, S.; He, B.; Esaias, C.E.; Frey, E.C.; Loeb, D.M.; Wahl, R.L.; Shokek, O.; Sgouros, G. A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. Int J Radiat Oncol Biol Phys. 2010 Oct 13.
Loeb, D.M.; Hobbs, R.F.; Okoli, A.; Chen, A.R.; Cho, S.; Srinivasan, S.; Sgouros, G.; Shokek, O.; Wharam, M.D., Jr.; Scott, T.; Schwartz, C.L. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer. 2010 Dec 1;116(23):5470-5478.
Loeb, S.; Makarov, D.V.; Schaeffer, E.M.; Humphreys, E.B.; Walsh, P.C. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. J Urol. 2010 Jul;184(1):157-161.
Loeb, S.; Partin, A.W. Open versus minimally invasive radical prostatectomy. Rev Urol. 2010 Winter;12(1):64-65.
Loeb, S.; Partin, A.W. What is the true mortality benefit of prostate-specific antigen screening? Rev Urol. 2010 Winter;12(1):66-67.
Loeb, S.; Partin, A.W. PCA3 Urinary Biomarker for Prostate Cancer. Rev Urol. 2010 Fall;12(4):e205-206.
Loeb, S.; Partin, A.W.; Schaeffer, E.M. Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? Rev Urol. 2010 Winter;12(1):20-24.
Loeb, S.; Schaeffer, E.M.; Epstein, J.I. The vanishing prostate cancer phenomenon. Urology. 2010 Sep;76(3):605-607.
Schaeffer, E.M.; Loeb, S.; Walsh, P.C. The case for open radical prostatectomy. Urol Clin North Am. 2010 Feb;37(1):49-55, Table of Contents.
Research Interests
- Cancer stem cells
More Info
Languages
- English
Memberships
American Association for Cancer Research, Childrens Oncology Group
Clinical Trials
- resistance to chemotherapy
- osteosarcoma
- soft tissue sarcomas
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts